Showing results (471-480 of 484) with videos related to

Sort By:
Pageof 49
The Lancet. Haematology|November 10, 2021
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma NetworkHeinz Ludwig, Pieter Sonneveld, Thierry Facon, et al.
Cancer Discovery|May 27, 2018
NRG1 Fusions in KRAS Wild-Type Pancreatic CancerChristoph Heining, Peter Horak, Sebastian Uhrig, et al.
Investigative Radiology|May 24, 2023
Prediction of Bone Marrow Biopsy Results From MRI in Multiple Myeloma Patients Using Deep Learning and RadiomicsMarkus Wennmann, Wenlong Ming, Fabian Bauer, et al.
Advances in Therapy|November 28, 2025
Comparative Efficacy of Talquetamab vs. Real-World Physician's Choice of Treatment in Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma: Updated Analyses of MonumenTAL-1 vs. LocoMMotion/MoMMentHermann Einsele, Philippe Moreau, Nizar Bahlis, et al.
Blood Cancer Discovery|June 2, 2022
Perspectives on the Risk-Stratified Treatment of Multiple MyelomaFaith E Davies, Charlotte Pawlyn, Saad Z Usmani, et al.
Leukemia|January 27, 2025
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myelomaLuciano J Costa, Rahul Banerjee, Hira Mian, et al.
The Lancet. Oncology|December 21, 2019
Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 studySagar Lonial, Hans C Lee, Ashraf Badros, et al.
BMC Cancer|September 7, 2021
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b studyGabriel Tremblay, Patrick Daniele, Janis Breeze, et al.
Haematologica|September 22, 2018
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTORAndrew Spencer, Suzanne Lentzsch, Katja Weisel, et al.
The Lancet. Oncology|May 2, 2024
International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myelomaPaula Rodriguez-Otero, Saad Usmani, Adam D Cohen, et al.
Pageof 49